Form 4: Adaptive Biotechnologies Exec Trades Shares

Adaptive Biotechnologies Corp. reports a transaction by Chief Commercial Officer Susan Bobulsky involving the sale of common stock.

Summary

• Susan Bobulsky, Chief Commercial Officer of Adaptive Biotechnologies Corp., sold 5,000 shares of common stock.
• The transaction occurred on June 25, 2026, at a price of $20.50 per share.
• This sale was executed as part of a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025.
• Following the transaction, Bobulsky beneficially owns 406,775 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves an insider selling stock, the transaction was conducted under a pre-established Rule 10b5-1 trading plan, mitigating concerns about opportunistic trading.

Negatives

• Insider selling of company stock can sometimes be perceived negatively by the market, although this transaction was conducted under a pre-established trading plan.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a stock transaction by an executive.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those executed under Rule 10b5-1 plans, are standard disclosures for insider stock transactions. The biotech industry often sees such transactions as executives manage their personal portfolios in line with company policies and pre-determined trading strategies.

Stakeholder Impact

• Shareholders: The sale of stock by an executive, even under a 10b5-1 plan, may lead to questions about the executive's confidence in the company's future performance, though the plan itself is designed to avoid insider trading concerns.

Key Dates

Keywords

Adaptive Biotechnologies Corp, ADPT, Form 4, Insider Trading, Rule 10b5-1, Stock Sale, Susan Bobulsky